Matthew Lin

3.0k total citations · 1 hit paper
10 papers, 899 citations indexed

About

Matthew Lin is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Matthew Lin has authored 10 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Matthew Lin's work include Nanoplatforms for cancer theranostics (3 papers), Nanoparticle-Based Drug Delivery (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Matthew Lin is often cited by papers focused on Nanoplatforms for cancer theranostics (3 papers), Nanoparticle-Based Drug Delivery (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Matthew Lin collaborates with scholars based in United States, China and Sweden. Matthew Lin's co-authors include Brian D. Brown, Judit Svensson‐Arvelund, Joshua Brody, Ignacio Melero, Aurélien Marabelle, Gabrielle S. Lubitz, Huan Meng, Xiangsheng Liu, Jinhong Jiang and Emily Zheng and has published in prestigious journals such as Advanced Functional Materials, The FASEB Journal and Small.

In The Last Decade

Matthew Lin

10 papers receiving 889 citations

Hit Papers

Cancer vaccines: the next immunotherapy frontier 2022 2026 2023 2024 2022 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew Lin United States 6 524 387 340 288 101 10 899
Aslan Mansurov United States 13 384 0.7× 351 0.9× 248 0.7× 200 0.7× 85 0.8× 18 808
Adam N.R. Cartwright United States 10 607 1.2× 415 1.1× 345 1.0× 272 0.9× 117 1.2× 11 1.0k
Laura Jeanbart Switzerland 9 654 1.2× 372 1.0× 399 1.2× 265 0.9× 87 0.9× 10 1.0k
Lauren E. Milling United States 9 485 0.9× 238 0.6× 257 0.8× 263 0.9× 144 1.4× 11 787
Jan Willem Kleinovink Netherlands 14 586 1.1× 313 0.8× 308 0.9× 377 1.3× 115 1.1× 20 966
Iraklis C. Kourtis Switzerland 5 602 1.1× 350 0.9× 308 0.9× 152 0.5× 83 0.8× 5 916
Hathaichanok Phuengkham United States 11 503 1.0× 301 0.8× 308 0.9× 572 2.0× 161 1.6× 17 955
Peyman Hosseinchi United States 8 430 0.8× 402 1.0× 215 0.6× 163 0.6× 58 0.6× 9 717
Ting Su China 11 530 1.0× 185 0.5× 324 1.0× 270 0.9× 109 1.1× 21 784
Miguel C. Sobral United States 11 549 1.0× 329 0.9× 346 1.0× 379 1.3× 102 1.0× 15 865

Countries citing papers authored by Matthew Lin

Since Specialization
Citations

This map shows the geographic impact of Matthew Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Lin more than expected).

Fields of papers citing papers by Matthew Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Lin. The network helps show where Matthew Lin may publish in the future.

Co-authorship network of co-authors of Matthew Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Lin. A scholar is included among the top collaborators of Matthew Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Lin. Matthew Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Chen, Grant H., et al.. (2025). The Effectiveness and Safety of Stellate Ganglion Block in the Treatment of Symptoms from Long COVID-19: A Pilot Study. Psychopharmacology Bulletin. 54(4). 8–17. 2 indexed citations
2.
Lin, Matthew, Danielle P. Dubin, Richard L. Torbeck, et al.. (2023). Early Fractional Ablative Laser for Skin Cancer Excision Scars: A Randomized Split-Scar Study. Dermatologic Surgery. 49(4). 338–342. 7 indexed citations
3.
Lin, Matthew, Judit Svensson‐Arvelund, Gabrielle S. Lubitz, et al.. (2022). Cancer vaccines: the next immunotherapy frontier. Nature Cancer. 3(8). 911–926. 553 indexed citations breakdown →
4.
Upadhyay, Ranjan, Jonathan Boiarsky, Judit Svensson‐Arvelund, et al.. (2021). A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery. 11(3). 599–613. 125 indexed citations
5.
Liu, Xiangsheng, Jinhong Jiang, Chong Hyun Chang, et al.. (2021). Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo‐Immunotherapy. Small. 17(14). e2005993–e2005993. 67 indexed citations
6.
Liu, Xiangsheng, Xiaodong Xie, Jinhong Jiang, et al.. (2021). Use of Nanoformulation to Target Macrophages for Disease Treatment. Advanced Functional Materials. 31(38). 29 indexed citations
7.
Liu, Xiangsheng, Jinhong Jiang, Yu‐Pei Liao, et al.. (2021). Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1. Advanced Science. 8(6). 2002147–2002147. 106 indexed citations
10.
Wu, Jianguo, et al.. (2017). Pyruvate Dehydrogenase Kinase 4‐Deficiency Induces Hepatic Apoptosis by Activating NF‐κB/TNFα Signaling. The FASEB Journal. 31(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026